BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference.

BioXcel Therapeutics announced that CEO Vimal Mehta will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Aug. 12, 2025, at 12 p.m. ET. The webcast will be available on the company's website for 90 days. BioXcel Therapeutics is a biopharmaceutical company using AI to develop transformative medicines in neuroscience.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence (AI) to develop transformative medicines in neuroscience, has announced that its CEO, Vimal Mehta, Ph.D., will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 12 p.m. ET. The event will take place in Boston, and investors can access the webcast through the company's website under the "Events & Presentations" page. The replay will be available for 90 days [1].

BioXcel Therapeutics is committed to re-innovating drugs using big data and proprietary machine learning algorithms. Its wholly owned subsidiary, OnkosXcel Therapeutics, focuses on developing medicines in immuno-oncology. The company's innovative approach aims to identify new therapeutic indications for existing approved drugs and clinically validated product candidates [2].

The fireside chat will provide an opportunity for investors and industry professionals to hear directly from CEO Vimal Mehta about BioXcel Therapeutics' progress, future plans, and the potential of AI in drug discovery and development. The event is expected to shed light on the company's pipeline, including product candidates such as IGALMI®, BXCL501, BXCL502, BXCL701, and BXCL702.

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130781/0/en/BioXcel-Therapeutics-to-Participate-in-Canaccord-Genuity-45th-Annual-Growth-Conference.html
[2] https://www.stocktitan.net/news/BTAI/bio-xcel-therapeutics-to-participate-in-canaccord-genuity-45th-ijfsv8m1ht4x.html